Thelansis

Axial Spondyloarthritis (axSpA) Market Outlook Thelansis’s “Axial Spondyloarthritis (axSpA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Axial Spondyloarthritis (axSpA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

Axial Spondyloarthritis (axSpA) Market Outlook Thelansis’s “Axial Spondyloarthritis (axSpA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Axial Spondyloarthritis (axSpA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Axial Spondyloarthritis (axSpA) Overview Axial spondyloarthritis (axSpA), which includes both ankylosing spondylitis (AS) and non-radiographic axial SpA, is the most common type of chronic inflammatory arthritis affecting the axial skeleton (AS). AS affects 0.1–0.5 percent of the population and is characterized by inflammatory back pain, radiographic sacroiliitis, excess spinal bone formation, and a high preval...